William Michael Rosellini
Fondateur chez Cytoimmune Therapeutics, Inc.
Postes actifs de William Michael Rosellini
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Fondateur | 01/06/2019 | - |
Public Communications Contact | 01/06/2019 | - | |
President | 01/06/2019 | - |
Historique de carrière de William Michael Rosellini
Anciens postes connus de William Michael Rosellini
Sociétés | Poste | Début | Fin |
---|---|---|---|
NEXEON MEDSYSTEMS INC | Directeur/Membre du Conseil | 07/12/2015 | - |
Directeur Général | 07/12/2015 | 22/10/2020 | |
Président | - | 22/10/2020 | |
President | 07/12/2015 | 01/12/2016 | |
Rosellini Scientific LLC
Rosellini Scientific LLC Medical SpecialtiesHealth Technology Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini. | Président | 01/01/2005 | 01/12/2016 |
Fondateur | 01/01/2005 | 01/12/2016 | |
MARATHON DIGITAL HOLDINGS, INC. | Directeur/Membre du Conseil | 01/01/2013 | 01/09/2016 |
Independent Dir/Board Member | 01/01/2013 | 01/09/2016 | |
The University of Texas at Dallas | Corporate Officer/Principal | 01/05/2013 | 01/08/2015 |
Sarif Biomedical LLC
Sarif Biomedical LLC Medical SpecialtiesHealth Technology Part of Marathon Digital Holdings, Inc., Sarif Biomedical LLC is a company that manufactures surgery related equipment. The company is based in Tool, TX. Sarif Biomedical was acquired by Marathon Digital Holdings, Inc. on May 02, 2014 for $0.55 million. | Directeur Général | 01/06/2013 | 01/08/2014 |
Lexington Technology Group, Inc. | Directeur Général | 01/06/2012 | 01/12/2013 |
Nuviant Medical, Inc.
Nuviant Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Nuviant Medical, Inc. provides janitorial services. The firm offers commercial and healthcare cleaning services. The company was founded in 1997 and is headquartered in Dallas, TX. | Directeur/Membre du Conseil | 01/12/2014 | - |
Directeur Général | 01/12/2014 | - | |
Fondateur | 01/12/2014 | - | |
Texas Onsite Dental | Fondateur | - | - |
President | - | - | |
░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de William Michael Rosellini
University of Dallas | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
Rutgers State University of New Jersey | Graduate Degree |
University of Southern California | Graduate Degree |
Maurice A. Deane School of Law at Hofstra University | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 14 |
France | 2 |
2 |
Opérationnelle
Founder | 5 |
President | 4 |
Graduate Degree | 4 |
Sectorielle
Consumer Services | 7 |
Health Technology | 6 |
Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
MARATHON DIGITAL HOLDINGS, INC. | Technology Services |
NEXEON MEDSYSTEMS INC | Health Technology |
Entreprise privées | 7 |
---|---|
MicroTransponder, Inc.
MicroTransponder, Inc. Medical SpecialtiesHealth Technology MicroTransponder, Inc. develops wireless neurostimulation system for the treatment of chronic pain and other neurological indications. It is a medical device company spun out from the University of Texas at Dallas. The firm has an team of neuroengineers collaborating with academics to develop wireless solutions to treat neurological diseases. The company was founded by Lawrence James Cauller, Thomas James Curnes II and William Michael Rosellini in June 2009 and is headquartered in Austin, TX. | Health Technology |
Texas Onsite Dental | |
Rosellini Scientific LLC
Rosellini Scientific LLC Medical SpecialtiesHealth Technology Rosellini Scientific LLC develops medical rehabilitation devices. The private company is based in Lexington, KY and has subsidiaries in the United States. The company was founded by William Michael Rosellini. | Health Technology |
Nuviant Medical, Inc.
Nuviant Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Nuviant Medical, Inc. provides janitorial services. The firm offers commercial and healthcare cleaning services. The company was founded in 1997 and is headquartered in Dallas, TX. | Commercial Services |
Sarif Biomedical LLC
Sarif Biomedical LLC Medical SpecialtiesHealth Technology Part of Marathon Digital Holdings, Inc., Sarif Biomedical LLC is a company that manufactures surgery related equipment. The company is based in Tool, TX. Sarif Biomedical was acquired by Marathon Digital Holdings, Inc. on May 02, 2014 for $0.55 million. | Health Technology |
Lexington Technology Group, Inc. | Finance |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Health Technology |
- Bourse
- Insiders
- William Michael Rosellini
- Expérience